The tissue-type plasminogen activator story

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 8, 2009, Pages 1151-1155

  Collen, D ^a   Lijnen, H R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Acute myocardial infarction; Pharmacological reperfusion; Thrombolytic therapy

Indexed keywords

ALTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; HUMAN; KIDNEY ALLOGRAFT; LUNG EMBOLISM; MELANOMA; MELANOMA CELL; MOLECULAR CLONING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOSIS; ANIMAL; ARTICLE; BLOOD; FIBRINOLYTIC THERAPY; HISTORY; METHODOLOGY; SYNTHESIS;

ANIMALS; FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 68149165545     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.179655     Document Type: Review

References (26)

1. Astrup T, Stage A. Isolation of a soluble fibrinolytic activator from animal tissue. Nature. 1952;170:929.
2. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69:209-216.
3. Rijken DC, Wijngaards G, Zaal-de Jong M, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta. 1979;580:140-153.
4. Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res. 1980;18:815-830.
5. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981;256:7035-7041.
6. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982;257:2912-2919.
7. Rijken DC, Juhan-Vague I, De Cock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med. 1983;101:274-284.
8. Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human extrinsic (tissue-type) plasminogen activator in centigram quantities from a human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemost. 1982;48:294-296.
9. Wiman B, Collen D. Molecular model of physiological fibrinolysis. Nature. 1978;272:549-550.
10. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost. 1980;43:77-89.
11. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983;301:214-221.
12. Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost. 1991;66:88-110.
13. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981;291:590-591.
14. Bergmann SR, Fox KAA, Ter-Pogossian MM, Sobel BE, Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science. 1983;220:1181-1183.
15. Weimar W, Stibbe J, van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet. 1981;2:1018-1020.
16. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KAA, De Geest H, Verstraete M, Collen D, Sobel B. Clot-selective coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984;310:609-613.
17. Van de Werf F, Bergmann SR, Fox KAA, de Geest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation. 1984;69:605-610.
18. Gold HK, Fallon JT, Yasuda T, Khaw BA, Newell JB, Leinbach RC, Guerrero JL, Vislosky FM, Hoyng CF, Gorssbard E, Collen D. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation. 1984;70:700-707.
19. Flameng W, Van de Werf F, Vanhaecke J, Verstraete M, Collen D. Coronary thrombolysis and infarct size reduction following intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates. J Clin Invest. 1985;75:84-90.
20. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RE, Brinker JA, Ludbrook PA, Yasuda T, Bulkley BH, Robison AK, Hutter AM, Bell WR, Spadaro JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984;70:1012-1017.
21. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
22. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
23. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1989;14: 1566-1569.
24. COBALT investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med. 1997;337:1124-1130.
25. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost. 2005;93: 627-630.
26. Lijnen HR, Collen D. New thrombolytic agents. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice, V Ed. (R.W. Colman, V.J. Marder, A.W. Clowes, J.N. George, S.Z. Goldhaber, Eds). Lippincott Williams & Wilkins, Philadelphia 2006, 1753-1761.